{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T16:11:19Z","timestamp":1787501479101,"version":"build-2736575974"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:00:00Z","timestamp":1781308800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":45,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The spread of lung cancer to bone is a devastating complication often linked to resistance against immunotherapy, but the reasons for this connection are poorly understood. Here we show that the transcription factor YBX1 acts as a central regulator driving both bone metastasis and the formation of an immunosuppressive environment in non-small cell lung cancer (NSCLC). YBX1 achieves this by activating distinct signaling pathways (IL6 and CCL5, respectively). Mechanistically, YBX1 protein levels are controlled by glycosylation that marks it for autophagic degradation inside cells. Notably, reduced YBX1 glycosylation was observed in highly bone-metastatic NSCLC cells. Importantly, we identified a drug candidate, Icaritin, which boosts this sugar-modification, leading to YBX1 degradation. This dual action inhibits bone metastasis and re-sensitizes tumors to immune attack. Our work reveals YBX1 as a promising single target for combating bone spread and overcoming immunotherapy resistance.<\/jats:p>","DOI":"10.1038\/s41467-026-73931-2","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T11:35:21Z","timestamp":1781350521000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["YBX1 Confers immunosuppressive bone metastatic traits in non-small cell lung cancer"],"prefix":"10.1038","volume":"17","author":[{"given":"Kai","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1714-1737","authenticated-orcid":false,"given":"Qingshui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyao","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengyang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihui","family":"Liang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijie","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0493-0155","authenticated-orcid":false,"given":"Yao","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8129-8926","authenticated-orcid":false,"given":"Lilin","family":"Ge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,13]]},"reference":[{"key":"73931_CR1","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.mcna.2018.12.006","volume":"103","author":"F Nasim","year":"2019","unstructured":"Nasim, F., Sabath, B. F. & Eapen, G. A. Lung Cancer.  Med. Clin. North Am. 103, 463\u2013473 (2019).","journal-title":"Med. Clin. North Am."},{"key":"73931_CR2","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.lungcan.2007.03.013","volume":"57","author":"A Tsuya","year":"2007","unstructured":"Tsuya, A., Kurata, T., Tamura, K. & Fukuoka, M. Skeletal metastases in non-small cell lung cancer: a retrospective study. Lung Cancer 57, 229\u2013232 (2007).","journal-title":"Lung Cancer"},{"key":"73931_CR3","first-page":"337","volume":"55","author":"C Greco","year":"2011","unstructured":"Greco, C., Forte, L., Erba, P. & Mariani, G. Bone metastases, general and clinical issues.  Q. J. Nucl. Med. Mol. Imaging.55, 337\u2013352 (2011).","journal-title":"Q. J. Nucl. Med. Mol. Imaging."},{"key":"73931_CR4","doi-asserted-by":"publisher","first-page":"2099","DOI":"10.1002\/jbmr.3618","volume":"33","author":"J Fornetti","year":"2018","unstructured":"Fornetti, J., Welm, A. L. & Stewart, S. A. Understanding the bone in cancer metastasis. J. Bone Miner. Res. 33, 2099\u20132113 (2018).","journal-title":"J. Bone Miner. Res."},{"key":"73931_CR5","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/sj.cr.7290266","volume":"15","author":"JJ Yin","year":"2005","unstructured":"Yin, J. J., Pollock, C. B. & Kelly, K. Mechanisms of cancer metastasis to the bone. Cell Res. 15, 57\u201362 (2005).","journal-title":"Cell Res."},{"key":"73931_CR6","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1038\/s41571-021-00499-9","volume":"18","author":"LC Hofbauer","year":"2021","unstructured":"Hofbauer, L. C. et al. Novel approaches to target the microenvironment of bone metastasis. Nat. Rev. Clin. Oncol. 18, 488\u2013505 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"73931_CR7","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2023.1188310","volume":"13","author":"Q Han","year":"2023","unstructured":"Han, Q. et al. The relationship between the Hippo signaling pathway and bone metastasis of breast cancer. Front. Oncol. 13, 1188310 (2023).","journal-title":"Front. Oncol."},{"key":"73931_CR8","doi-asserted-by":"crossref","unstructured":"Hamza, F. N. & Mohammad, K. S. Immunotherapy in the battle against bone metastases: mechanisms and emerging treatments. Pharmaceuticals 17, 1591 (2024).","DOI":"10.3390\/ph17121591"},{"key":"73931_CR9","doi-asserted-by":"crossref","unstructured":"Del Conte, A. et al. Bone metastasis and immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): microenvironment and possible clinical implications. Int. J. Mol. Sci. 23, 6832 (2022).","DOI":"10.3390\/ijms23126832"},{"key":"73931_CR10","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.semcancer.2022.08.001","volume":"86","author":"Y Li","year":"2022","unstructured":"Li, Y., Azmi, A. S. & Mohammad, R. M. Deregulated transcription factors and poor clinical outcomes in cancer patients. Semin. Cancer Biol. 86, 122\u2013134 (2022).","journal-title":"Semin. Cancer Biol."},{"key":"73931_CR11","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/annonc\/mdx702","volume":"29","author":"WH Hsu","year":"2018","unstructured":"Hsu, W. H., Yang, J. C., Mok, T. S. & Loong, H. H. Overview of current systemic management of EGFR-mutant NSCLC. Ann. Oncol. 29, i3\u2013i9 (2018).","journal-title":"Ann. Oncol."},{"key":"73931_CR12","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1097\/JTO.0000000000000069","volume":"9","author":"DY Shin","year":"2014","unstructured":"Shin, D. Y. et al. EGFR mutation and brain metastasis in pulmonary adenocarcinomas. J. Thorac. Oncol. 9, 195\u2013199 (2014).","journal-title":"J. Thorac. Oncol."},{"key":"73931_CR13","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202411834","volume":"12","author":"H Wang","year":"2025","unstructured":"Wang, H. et al. N4-Acetylcytidine-mediated CD2BP2-DT drives YBX1 phase separation to stabilize CDK1 and promote breast cancer progression. Adv. Sci. 12, e2411834 (2025).","journal-title":"Adv. Sci."},{"key":"73931_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.metabol.2024.155914","volume":"156","author":"H Zhu","year":"2024","unstructured":"Zhu, H. et al. O-GlcNAcylation promotes the progression of nonalcoholic fatty liver disease by upregulating the expression and function of CD36. Metab. Clin. Exp. 156, 155914 (2024).","journal-title":"Metab. Clin. Exp."},{"key":"73931_CR15","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1016\/j.chembiol.2025.05.007","volume":"32","author":"Y Zhang","year":"2025","unstructured":"Zhang, Y. et al. EGR2 O-GlcNAcylation orchestrates the development of protumoral macrophages to limit CD8(+) T cell antitumor responses. Cell Chem. Biol. 32, 809\u2013825.e807 (2025).","journal-title":"Cell Chem. Biol."},{"key":"73931_CR16","doi-asserted-by":"crossref","unstructured":"Maeda, K. et al. Inflammation and bone metabolism in rheumatoid arthritis: molecular mechanisms of joint destruction and pharmacological treatments. Int. J. Mol. Sci. 23, 2871 (2022).","DOI":"10.3390\/ijms23052871"},{"key":"73931_CR17","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1038\/s43018-022-00448-0","volume":"3","author":"L Tian","year":"2022","unstructured":"Tian, L. et al. Specific targeting of glioblastoma with an oncolytic virus expressing a cetuximab-CCL5 fusion protein via innate and adaptive immunity. Nat. Cancer 3, 1318\u20131335 (2022).","journal-title":"Nat. Cancer"},{"key":"73931_CR18","doi-asserted-by":"crossref","unstructured":"Xu, J. et al. Chordoma recruits and polarizes tumor-associated macrophages via secreting CCL5 to promote malignant progression. J. Immunother. Cancer 11, e006808 (2023).","DOI":"10.1136\/jitc-2023-006808"},{"key":"73931_CR19","doi-asserted-by":"publisher","first-page":"2390","DOI":"10.1038\/s12276-023-01108-8","volume":"55","author":"J Yu","year":"2023","unstructured":"Yu, J. et al. Circular RNA cFAM210A, degradable by HBx, inhibits HCC tumorigenesis by suppressing YBX1 transactivation. Exp. Mol. Med. 55, 2390\u20132401 (2023).","journal-title":"Exp. Mol. Med."},{"key":"73931_CR20","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1038\/s12276-024-01184-4","volume":"56","author":"X Liu","year":"2024","unstructured":"Liu, X. et al. RNA m(5)C modification upregulates E2F1 expression in a manner dependent on YBX1 phase separation and promotes tumor progression in ovarian cancer. Exp. Mol. Med. 56, 600\u2013615 (2024).","journal-title":"Exp. Mol. Med."},{"key":"73931_CR21","doi-asserted-by":"publisher","first-page":"2770","DOI":"10.1111\/cas.14928","volume":"112","author":"H Shi","year":"2021","unstructured":"Shi, H. et al. CEBP\u03b3 facilitates lamellipodia formation and cancer cell migration through CERS6 upregulation. Cancer Sci. 112, 2770\u20132780 (2021).","journal-title":"Cancer Sci."},{"key":"73931_CR22","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/cac2.12539","volume":"44","author":"GR Khosravi","year":"2024","unstructured":"Khosravi, G. R. et al. Immunologic tumor microenvironment modulators for turning cold tumors hot. Cancer Commun. 44, 521\u2013553 (2024).","journal-title":"Cancer Commun."},{"key":"73931_CR23","doi-asserted-by":"publisher","first-page":"14058","DOI":"10.3390\/cimb46120841","volume":"46","author":"W Zhang","year":"2024","unstructured":"Zhang, W. et al. YBX1: A multifunctional protein in senescence and immune regulation. Curr. Issues Mol. Biol. 46, 14058\u201314079 (2024).","journal-title":"Curr. Issues Mol. Biol."},{"key":"73931_CR24","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41392-020-00312-6","volume":"5","author":"H Yu","year":"2020","unstructured":"Yu, H., Lin, L., Zhang, Z., Zhang, H. & Hu, H. Targeting NF-\u03baB pathway for the therapy of diseases: mechanism and clinical study. Signal Transduct. Target. Ther. 5, 209 (2020).","journal-title":"Signal Transduct. Target. Ther."},{"key":"73931_CR25","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/nrc2734","volume":"9","author":"H Yu","year":"2009","unstructured":"Yu, H., Pardoll, D. & Jove, R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9, 798\u2013809 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"73931_CR26","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1007\/s13238-013-2084-3","volume":"4","author":"Y Fan","year":"2013","unstructured":"Fan, Y., Mao, R. & Yang, J. NF-\u03baB and STAT3 signaling pathways collaboratively link inflammation to cancer. Protein Cell 4, 176\u2013185 (2013).","journal-title":"Protein Cell"},{"key":"73931_CR27","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37161-0","volume":"14","author":"Y Bai","year":"2023","unstructured":"Bai, Y. et al. YBX1 integration of oncogenic PI3K\/mTOR signalling regulates the fitness of malignant epithelial cells. Nat. Commun. 14, 1591 (2023).","journal-title":"Nat. Commun."},{"key":"73931_CR28","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.kint.2023.09.014","volume":"105","author":"R Rana","year":"2024","unstructured":"Rana, R. et al. Glomerular-tubular crosstalk via cold shock Y-box binding protein-1 in the kidney. Kidney Int. 105, 65\u201383 (2024).","journal-title":"Kidney Int."},{"key":"73931_CR29","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1097\/CAD.0000000000000976","volume":"31","author":"X Zhao","year":"2020","unstructured":"Zhao, X. et al. Icaritin inhibits lung cancer-induced osteoclastogenesis by suppressing the expression of IL-6 and TNF-a and through AMPK\/mTOR signaling pathway. Anticancer Drugs 31, 1004\u20131011 (2020).","journal-title":"Anticancer Drugs"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73931-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73931-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73931-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T17:10:24Z","timestamp":1785517824000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-026-73931-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,13]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["73931"],"URL":"https:\/\/doi.org\/10.1038\/s41467-026-73931-2","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,13]]},"assertion":[{"value":"26 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"7505"}}